GLP-1s and Mood in Menopause: What the Research Actually Shows

For a while there were worries that GLP-1 medications might worsen mood or even raise suicidal thoughts, prompting regulators to investigate. The most recent and largest evidence is reassuring. A 2026 national cohort study published in *The Lancet Psychiatry*, using a within-person design in people with existing depression and anxiety, found that semaglutide was associated with a 42% lower risk of worsening mental illness — including a 44% lower risk of depression, a 38% lower risk of anxiety, and a 47% lower risk of substance use disorder — during treatment periods compared with non-treatment periods. It also found lower rates of psychiatric hospitalization and sick leave. Importantly for the earlier safety signal, the analysis found no increase in self-harm or suicide and, if anything, lower risk. This doesn't prove the drug improves mood, but it strongly argues against the fear that GLP-1s damage it. Understanding [how GLP-1s quiet 'food noise'](/blog/food-noise-on-glp-1-why-it-quiets-and-what-it-means) hints at how these drugs may touch brain reward pathways.

Menopause is a genuinely vulnerable window for mood. Fluctuating and then falling estrogen affects serotonin and other neurotransmitters, and studies show the risk of depression and anxiety rises during the menopause transition, even in women with no prior history. Sleep disruption from night sweats, brain fog, and life stressors compound the effect. So a woman in perimenopause or menopause who's also considering a GLP-1 for weight has two things happening at once: a life stage that pushes mood risk up, and a medication that — based on current data — doesn't appear to add to that risk and may coincide with improvement. This is exactly the kind of overlap Lea focuses on. For the mood side specifically, our guide on [why your mood drops in menopause and what helps](/blog/menopause-depression-why-your-mood-drops-and-what-helps) covers the hormonal mechanisms in detail.

Very possibly — and this is part of why the research is hard to interpret. When people lose weight and feel physically better, mobility, self-image, sleep, and blood-sugar stability often improve, all of which can lift mood. So some of the mental-health benefit seen with GLP-1s may come indirectly from weight loss and better metabolic health rather than a direct brain effect of the drug. There may also be a direct component: GLP-1 receptors exist in brain regions involved in reward and stress, which is why researchers are actively studying these drugs for mood and addiction. The honest answer is that both mechanisms probably contribute, and untangling them is ongoing. What matters practically is the bottom line from large datasets: mood outcomes on these drugs look neutral to favorable, not harmful — a meaningful reassurance for midlife women weighing their options.

Based on current evidence, GLP-1s do not appear to worsen depression — and may be associated with lower risk — but "reassuring" is not "risk-free for everyone." Individuals vary, and anyone with a history of depression, anxiety, or an eating disorder should start a GLP-1 with their mood on the radar and their care team informed. Rapid appetite suppression can occasionally affect people's relationship with food in complicated ways, and undereating can itself dampen mood and energy. Practical monitoring helps: check in with yourself weekly, keep protein and hydration up, and flag any persistent low mood, loss of interest, or worsening anxiety to your provider early. If you take antidepressants, don't change them on your own. This kind of dual tracking — metabolic and emotional — is the safest way to benefit from the medication while catching any problems fast.

Think of it as one integrated plan rather than two separate projects. Protect muscle and energy with adequate protein and strength training, which supports both metabolism and mood. Prioritize sleep, treating night sweats if they're wrecking it, because poor sleep undermines everything else. Keep social connection and movement in the picture — both are evidence-based mood supports that also aid weight maintenance. If you're using hormones, know that HRT and GLP-1s can be complementary; our deep dive on [GLP-1s and HRT together (the Weill Cornell study)](/blog/glp-1s-and-hrt-together-the-weill-cornell-study-and-what-it-means) explains the emerging synergy. And don't neglect cognition — the same period brings [menopause brain fog](/blog/menopause-brain-fog-causes-and-evidence-based-solutions) for many. The goal is a midlife plan where the medication is one supported piece, wrapped in habits that protect your mind as much as your metabolism. Build it with your clinician, and revisit it as your body changes.

It's important to be honest about what we don't yet know. The most encouraging findings, including the 2026 Lancet Psychiatry study, are observational — they compare treated and untreated periods but cannot fully rule out confounding factors, so they show association, not proof of cause. Randomized trials designed specifically to measure mood as a primary outcome are still limited, and most data pools men and women together rather than isolating menopausal women. That means the specific question "how do GLP-1s affect mood *during menopause*?" hasn't been answered by a dedicated trial yet — we're reasoning from broader evidence. The takeaway is balanced optimism: the safety signal that once caused alarm has not held up, the overall picture looks favorable, but you should still treat your own experience as the most important data point and stay in dialogue with your healthcare team. For the depression-specific evidence, see our summary of the [Lancet Psychiatry findings on GLP-1s and depression](/blog/glp-1s-and-depression-lancet-psychiatry-study-insights).